Compare RYTM & DOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | DOO |
|---|---|---|
| Founded | 2008 | 1937 |
| Country | United States | Canada |
| Employees | N/A | 17000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2017 | N/A |
| Metric | RYTM | DOO |
|---|---|---|
| Price | $88.26 | $58.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $131.14 | $85.67 |
| AVG Volume (30 Days) | ★ 491.0K | 225.1K |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 1.21% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.34 | $8.48 |
| Revenue Next Year | $86.06 | $5.10 |
| P/E Ratio | ★ N/A | $338.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.71 | $48.83 |
| 52 Week High | $122.20 | $81.89 |
| Indicator | RYTM | DOO |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 48.34 |
| Support Level | $87.19 | $52.66 |
| Resistance Level | $92.51 | $63.86 |
| Average True Range (ATR) | 3.56 | 2.75 |
| MACD | -0.24 | 0.45 |
| Stochastic Oscillator | 49.10 | 51.15 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, the company sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.